Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry

[1]  T. Aoyama,et al.  Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype. , 1991, Pharmacogenetics.

[2]  P. Bertazzi,et al.  Gene-environment interaction in parkinson's disease. The case of CYP2D6 gene polymorphism. , 1996, Advances in neurology.

[3]  J. Idle,et al.  Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase. , 2003, Pharmacogenetics.

[4]  I. Kanazawa,et al.  Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. , 1993, Pharmacogenetics.

[5]  D. Nebert,et al.  Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22. , 1988, Genomics.

[6]  S. Yamazaki,et al.  Importance of the proline-rich region following signal-anchor sequence in the formation of correct conformation of microsomal cytochrome P-450s. , 1993, Journal of biochemistry.

[7]  R. Skoda,et al.  Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[8]  M Schwab,et al.  Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. , 2000, Pharmacogenetics.

[9]  U. Meyer,et al.  Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man. , 1988, Biochemistry.

[10]  A. S. Gross,et al.  The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects. , 1990, Pharmacology & therapeutics.

[11]  D. Nebert,et al.  Characterization of the common genetic defect in humans deficient in debrisoquine metabolism , 1988, Nature.

[12]  C. Bouras,et al.  Cytochrome P-450 activities in human and rat brain microsomes , 2000, Brain Research.

[13]  L. Bertilsson,et al.  Polymorphic oxidation of sparteine and debrisoquine: Related pharmacogenetic entities , 1982, Clinical pharmacology and therapeutics.

[14]  W. V. Shaw,et al.  Structural and Mechanistic Studies of Galactoside Acetyltransferase, the Escherichia coli LacA Gene Product (*) , 1995, The Journal of Biological Chemistry.

[15]  W. Koch,et al.  Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. , 2003, Clinical chemistry.

[16]  L. Bertilsson,et al.  Polymorphic debrisoquin hydroxylation in 757 Swedish subjects , 1988, Clinical pharmacology and therapeutics.

[17]  Melanie E. Goward,et al.  The DNA sequence of human chromosome 22 , 1999, Nature.

[18]  F Peter Guengerich,et al.  Role of glutamic acid 216 in cytochrome P450 2D6 substrate binding and catalysis. , 2003, Biochemistry.

[19]  Michael Böhm,et al.  Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol‐associated adverse effects , 2002, Clinical pharmacology and therapeutics.

[20]  M Ingelman-Sundberg,et al.  Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. , 1996, The Journal of pharmacology and experimental therapeutics.

[21]  J. Poirier,et al.  ECOGENETICS OF PARKINSON'S DISEASE: 4-HYDROXYLATION OF DEBRISOQUINE , 1985, The Lancet.

[22]  Ai-Ming Yu,et al.  Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. , 2003, Pharmacogenetics.

[23]  M. Brodie,et al.  Assay and characterisation of debrisoquine 4-hydroxylase activity of microsomal fractions of human liver. , 1982, British journal of clinical pharmacology.

[24]  W. Haefeli,et al.  Potent Inhibition of Cytochrome P450IID6 (Debrisoquin 4‐Hydroxylase) by Flecainide In Vitro and In Vivo , 1990, Journal of cardiovascular pharmacology.

[25]  U. Meyer,et al.  MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation. , 1987, Biochemical and biophysical research communications.

[26]  U. Meyer,et al.  Multiple Mutations of the Human Cytochrome P 450 IID 6 Gene ( CYP 2 D 6 ) in Poor Metabolizers of Debrisoquine , 2001 .

[27]  A. Molven,et al.  Ultrarapid metabolizers of debrisoquine: Characterization and PCR‐based detection of alleles with duplication of the CYP2D6 gene , 1996, FEBS letters.

[28]  U. Meyer,et al.  The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934----A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3' splice recognition site. , 1990, American journal of human genetics.

[29]  Sharon Miksys,et al.  Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics , 2002, Journal of neurochemistry.

[30]  U. Meyer,et al.  An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis. , 1995, Pharmacogenetics.

[31]  M. Ingelman-Sundberg,et al.  Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. , 1995, The Journal of pharmacology and experimental therapeutics.

[32]  U. Meyer,et al.  Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification , 1990, The Lancet.

[33]  J. Brockmöller,et al.  The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment , 2002, Clinical pharmacology and therapeutics.

[34]  G. Gervasini,et al.  Tryptamine: a possible endogenous substrate for CYP2D6. , 1997, Pharmacogenetics.

[35]  James M. Eldred,et al.  The DNA sequence of human chromosome 7 , 2003, Nature.

[36]  M. Eichelbaum,et al.  The influence of enzyme induction on polymorphic sparteine oxidation. , 1986, British journal of clinical pharmacology.

[37]  J. Lafitte,et al.  Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. , 1997, Pharmacogenetics.

[38]  M. Eichelbaum,et al.  CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real‐rime PCR , 2003, Human mutation.

[39]  S. Imaoka,et al.  Dopamine formation from tyramine by CYP2D6. , 1998, Biochemical and biophysical research communications.

[40]  M. Ingelman-Sundberg,et al.  Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction. , 1998, Pharmacogenetics.

[41]  L. Kaminsky,et al.  Alternative splicing of CYP2D mRNA in human breast tissue. , 1997, Archives of biochemistry and biophysics.

[42]  J. Idle,et al.  POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN , 1977, The Lancet.

[43]  T. Eschenhagen,et al.  Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. , 2002, Pharmacogenetics.

[44]  S A van Acker,et al.  A predictive model for substrates of cytochrome P450-debrisoquine (2D6). , 1992, Chemical research in toxicology.

[45]  G. Tucker,et al.  Oxidation phenotype--a major determinant of metoprolol metabolism and response. , 1982, The New England journal of medicine.

[46]  M. Ingelman-Sundberg,et al.  Human cytochrome P450 (CYP) genes: recommendations for the nomenclature of alleles. , 2000, Pharmacogenetics.

[47]  S. Kasper,et al.  CYP2D6 and CYP2C19 genotype‐based dose recommendations for antidepressants:
a first step towards subpopulation‐specific dosages , 2001, Acta psychiatrica Scandinavica.

[48]  T. Kronbach,et al.  Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol. , 1986, The Journal of biological chemistry.

[49]  M. Ingelman-Sundberg,et al.  Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. , 1994, Molecular pharmacology.

[50]  T. Kronbach,et al.  In vitro characterization of the human cytochrome P‐450 involved in polymorphic oxidation of propafenone , 1989, Clinical pharmacology and therapeutics.

[51]  U. Meyer,et al.  Molecular mechanisms of genetic polymorphisms of drug metabolism. , 1997, Annual review of pharmacology and toxicology.

[52]  L. Bertilsson,et al.  Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. , 1985, Therapeutic drug monitoring.

[53]  H. Kroemer,et al.  Use of Probe Drugs as Predictors of Drug Metabolism in Humans , 1997, Journal of clinical pharmacology.

[54]  G. Tucker,et al.  Polymorphic drugoxidation: pharmacokinetic basis and comparison ofexperimental indices , 1986 .

[55]  M. Ingelman-Sundberg,et al.  Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[56]  M. Eichelbaum,et al.  Discriminative quantification of cytochrome P4502D6 and 2D7/8 pseudogene expression by TaqMan real-time reverse transcriptase polymerase chain reaction. , 2002, Analytical biochemistry.

[57]  G. Tucker,et al.  Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson's disease. , 1998, Pharmacogenetics.

[58]  J. Idle,et al.  Medical implications of HGP's sequence of chromosome 22 , 2000, The Lancet.

[59]  J. Brockmöller,et al.  Mutant genes of cytochrome P-450IID6, glutathione S-transferase class Mu, and arylamine N-acetyltransferase in lung cancer patients , 1992, The clinical investigator.

[60]  R. Branch,et al.  Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity. , 1994, Carcinogenesis.

[61]  N. Benowitz,et al.  Clinical significance of genetic influences on cardiovascular drug metabolism , 1993, Cardiovascular Drugs and Therapy.

[62]  L. Bertilsson,et al.  Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. , 1980, Life sciences.

[63]  U. Meyer.  Pharmacogenetics and adverse drug reactions , 2000, The Lancet.

[64]  F. Guengerich,et al.  Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. , 1985, The Journal of biological chemistry.

[65]  R. Branch,et al.  CYP2D6 mRNA expression in circulating peripheral blood mononuclear cells correlates with in vivo debrisoquine hydroxylase activity in extensive metabolizers. , 1996, Research communications in molecular pathology and pharmacology.

[66]  M. Eichelbaum,et al.  Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population. , 1999, Pharmacogenetics.

[67]  S. Dehal,et al.  CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. , 1997, Cancer research.

[68]  M. Eichelbaum,et al.  Functional properties of CYP2D6 1 (wild-type) and CYP2D6 7 (His324Pro) expressed by recombinant baculovirus in insect cells , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[69]  L. Bertilsson,et al.  Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment. , 1987, Pharmacology & toxicology.

[70]  M. Eichelbaum,et al.  Allele and genotype frequencies of polymorphic cytochromes P4502D6, 2C19 and 2E1 in aborigines from western Australia. , 2001, Pharmacogenetics.

[71]  J. Lindsten,et al.  A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin , 1985, Clinical pharmacology and therapeutics.

[72]  T. Prueksaritanont,et al.  (+)-bufuralol 1'-hydroxylation activity in human and rhesus monkey intestine and liver. , 1995, Biochemical pharmacology.

[73]  O. Andreassen,et al.  Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype. , 1996, Pharmacogenetics.

[74]  A. Daly,et al.  Pharmacogenetics of the major polymorphic metabolizing enzymes , 2003, Fundamental & clinical pharmacology.

[75]  Gordon C K Roberts,et al.  Residues Glutamate 216 and Aspartate 301 Are Key Determinants of Substrate Specificity and Product Regioselectivity in Cytochrome P450 2D6* , 2003, The Journal of Biological Chemistry.

[76]  K. Brøsen,et al.  Clinical significance of the sparteine/debrisoquine oxidation polymorphism , 2004, European Journal of Clinical Pharmacology.

[77]  R. Edwards,et al.  Expression of xenobiotic-metabolizing cytochrome P450s in human pulmonary tissues. , 1998, Archives of toxicology. Supplement. = Archiv fur Toxikologie. Supplement.

[78]  M. Eichelbaum,et al.  Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. , 2001, Pharmacogenetics.

[79]  J. S. Miles,et al.  Identification of the primary gene defect at the cytochrome P450 CYP2D locus , 1990, Nature.

[80]  J. Brockmöller,et al.  Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. , 1997, American journal of human genetics.

[81]  A. Molven,et al.  Homologous unequal cross-over involving a 2.8 kb direct repeat as a mechanism for the generation of allelic variants of human cytochrome P450 CYP2D6 gene. , 1995, Human molecular genetics.

[82]  Jose Cosme,et al.  Crystal structure of human cytochrome P450 2C9 with bound warfarin , 2003, Nature.

[83]  M. Ingelman-Sundberg,et al.  Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine , 1993, The Lancet.

[84]  E. Molden,et al.  Pharmacokinetics of diltiazem and its metabolites in relation to CYP2D6 genotype , 2002, Clinical pharmacology and therapeutics.

[85]  Chan,et al.  Gene—Environment Interaction in Parkinson‘s Disease , 2001 .

[86]  U. Meyer,et al.  Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene. , 1993, Pharmacogenetics.

[87]  J. Hallas,et al.  The relationship between paroxetine and the sparteine oxidation polymorphism , 1992, Clinical pharmacology and therapeutics.

[88]  M. Eichelbaum,et al.  The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. , 2002, British journal of clinical pharmacology.

[89]  J. Bircher,et al.  Polymorphic dextromethorphan metabolism: Co‐segregation of oxidative O‐demethylation with debrisoquin hydroxylation , 1985, Clinical pharmacology and therapeutics.

[90]  R. Poulsom,et al.  Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in situ hybridization. , 1997, Xenobiotica; the fate of foreign compounds in biological systems.

[91]  M. Eichelbaum,et al.  Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. , 1991, American journal of human genetics.

[92]  L. Bertilsson,et al.  Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. , 1995, Pharmacogenetics.

[93]  R. Kaiser,et al.  Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  F. Guengerich,et al.  Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling. , 1985, Cancer research.

[95]  M. Ingelman-Sundberg,et al.  Human CYP allele database: submission criteria procedures and objectives. , 2002, Methods in enzymology.

[96]  N. Rothman,et al.  Lung cancer and CYP2D6 (the debrisoquine polymorphism): sources of heterogeneity in the proposed association. , 1995, Pharmacogenetics.

[97]  H. Hauri,et al.  Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[98]  M. Ingelman-Sundberg,et al.  Nomenclature for human CYP2D6 alleles. , 1996, Pharmacogenetics.

[99]  A. Molven,et al.  Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism? , 2001, Pharmacogenetics.

[100]  Serge Léger,et al.  Diversity in the oxidation of substrates by cytochrome P450 2D6: lack of an obligatory role of aspartate 301-substrate electrostatic bonding. , 2002, Biochemistry.

[101]  U. Meyer,et al.  Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. , 1990, The Journal of biological chemistry.

[102]  M. Baur,et al.  Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22. , 1987, British journal of clinical pharmacology.

[103]  M. Eichelbaum,et al.  Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reaction. , 1996, Pharmacogenetics.

[104]  M. Eichelbaum,et al.  Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. , 1998, Pharmacogenetics.

[105]  M. Eichelbaum,et al.  Inter-ethnic difference in sparteine oxidation among Ghanaians and Germans , 2004, European Journal of Clinical Pharmacology.

[106]  M. Ingelman-Sundberg,et al.  Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. , 1999, Gene.

[107]  M. Relling,et al.  Pharmacogenomics: translating functional genomics into rational therapeutics. , 1999, Science.

[108]  M. Cronin,et al.  Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. , 2000, Journal of clinical psychopharmacology.

[109]  K. Brøsen,et al.  Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Danish University Antidepressant Group. , 1993, British journal of clinical pharmacology.

[110]  V. Steen,et al.  [22] CYP2D6 multiallelism , 1996 .

[111]  T. Kronbach,et al.  Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism)--increased Michaelis is Constant (Km) and loss of stereoselectivity of bufuralol 1'-hydroxylation in poor metabolizers. , 1984, Biochemical and biophysical research communications.

[112]  D. Flockhart,et al.  Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[113]  P. Gøtzsche,et al.  The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease: a meta-analysis. , 1998, Pharmacogenetics.

[114]  R. Blouin,et al.  The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: Screening costs and influence on clinical outcomes in psychiatry , 1996, Clinical pharmacology and therapeutics.

[115]  R. Lindberg,et al.  Inhibitory effects of neuroleptics on debrisoquine oxidation in man. , 1986, British journal of clinical pharmacology.

[116]  M. Hiratsuka,et al.  High throughput detection of drug-metabolizing enzyme polymorphisms by allele-specific fluorogenic 5' nuclease chain reaction assay. , 2000, Biological & pharmaceutical bulletin.

[117]  B. Pollock,et al.  CYP2D6 Genotyping with Oligonucleotide Microarrays and Nortriptyline Concentrations in Geriatric Depression , 2001, Neuropsychopharmacology.

[118]  A. Rettie,et al.  Expression, Purification, Biochemical Characterization, and Comparative Function of Human Cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 Allelic Isoforms , 2002, Journal of Pharmacology and Experimental Therapeutics.

[119]  M. Eichelbaum,et al.  Defective N-oxidation of sparteine in man: A new pharmacogenetic defect , 1979, European Journal of Clinical Pharmacology.

[120]  T. Kronbach.  Bufuralol, dextromethorphan, and debrisoquine as prototype substrates for human P450IID6. , 1991, Methods in enzymology.

[121]  S. London,et al.  CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. , 1998, Pharmacogenetics.

[122]  M. Lai,et al.  Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: Polymorphism in RFLP and DNA sequence of CYP2D6 , 1993, Clinical pharmacology and therapeutics.

[123]  M. Ingelman-Sundberg,et al.  PCR-based genotyping for duplicated and deleted CYP2D6 genes. , 1996, Pharmacogenetics.

[124]  M Schwab,et al.  Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. , 2001, Pharmacogenetics.

[125]  D. Shen,et al.  Comparison of CYP2D6 Content and Metoprolol Oxidation Between Microsomes Isolated from Human Livers and Small Intestines , 1999, Pharmaceutical Research.

[126]  M. Dahl.  Cytochrome P450 Phenotyping/Genotyping in Patients Receiving Antipsychotics , 2002, Clinical pharmacokinetics.

[127]  M. Ingelman-Sundberg,et al.  Duplication, multiduplication, and amplification of genes encoding drug-metabolizing enzymes: evolutionary, toxicological, and clinical pharmacological aspects. , 1999, Drug metabolism reviews.

[128]  T. Thum,et al.  Gene expression in distinct regions of the heart , 2000, The Lancet.

[129]  R. Skoda,et al.  The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. , 1989, American journal of human genetics.

[130]  M Ingelman-Sundberg,et al.  A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function. , 1997, Molecular pharmacology.

[131]  J. Idle,et al.  A polymorphic CfoI site in exon 6 of the human cytochrome P450 CYP2D6 gene detected by the polymerase chain reaction , 1993, Human Genetics.

[132]  M. Ingelman-Sundberg,et al.  Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs , 1996, European Journal of Clinical Pharmacology.

[133]  L. Bertilsson,et al.  10‐hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes , 1998, Clinical pharmacology and therapeutics.

[134]  B. Rochat,et al.  Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror , 1995, International clinical psychopharmacology.

[135]  H. Kroemer,et al.  Analysis of CYP2D6 expression in human lung: implications for the association between CYP2D6 activity and susceptibility to lung cancer. , 1997, Pharmacogenetics.

[136]  D. Schrenk,et al.  The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. , 1994, Pharmacogenetics.

[137]  M. Ingelman-Sundberg,et al.  A Combination of Mutations in the CYP 2 D 6 * 17 ( CYP 2 D 6 Z ) Allele Causes Alterations in Enzyme Function , 1997 .

[138]  M Ingelman-Sundberg,et al.  Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. , 1997, Pharmacogenetics.

[139]  S. Imaoka,et al.  The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6. , 2000, Archives of biochemistry and biophysics.

[140]  J. Lafitte,et al.  Evidence for CYP2D6 expression in human lung. , 1997, Biochemical and biophysical research communications.

[141]  G. Bertschy,et al.  Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. , 1995, Pharmacological research.

[142]  J. Benítez,et al.  Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population , 1995, Clinical pharmacology and therapeutics.

[143]  M. Relling,et al.  Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin‐oxidation and N‐acetylation phenotypes in children , 1989, Clinical pharmacology and therapeutics.

[144]  Michael J. E. Sternberg,et al.  Evidence That Aspartic Acid 301 Is a Critical Substrate-Contact Residue in the Active Site of Cytochrome P450 2D6 (*) , 1995, The Journal of Biological Chemistry.